

NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

DATA SHEET

Reagent: Anti-HIV-1 gp120 Monoclonal (2219)

Catalog Number: 11683

Lot Number: 110111

Release Category: Е

Provided: 10 μ L purified antibody, 4.84 μ g/ μ L, in PBS.

HIV-1 V3 mononclonal antibody (2219) purified from culture supernatant using Hi-Trap **Description:**

Protein A Sepharose High Performance Column.

Host Site: Human (EBV transformed B cell fused to SHM-D33 mousexhuman heteromyeloma

SHM-D33).

Titer: ELISA: 0.01-10 μg/mL

Special This antibody is directed against the V3 region of gp120. Confers broad cross-reactivity Characteristics: amoung Clade B viruses.

Recommended Keep at 4°C for short term storage and -80°C for long term storage. Avoid freeze-thaw

cycles as reagent degradation may result.

Contributor: Dr. Susan Zolla-Pazner.

Isotype: $IgG_1 \lambda$ chain.

Storage:

References:

Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, Polonis VR, Honnen WJ, Kayman SC, Krachmarov C, Pinter A, Zolla-Pazner S. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1

primary isolates from various clades. J Virol. 2002 Sep;76(18):9035-45.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 02/20/2015 Page 1 of 2 NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp120 Monoclonal (2219) from Dr. Susan Zolla-Pazner." Also include the references cited above in any publications.

Requests from commercial organizations must be directed in writing to Dr. Susan Zolla-Pazner at the Veterans Administration Medical Center, 423 East 23rd St., New York, NY 10010.

PLEASE NOTE: The contributor has requested to be informed at least two weeks before submitting a document for publication or making a public oral presentation of research results obtained from the use of this material, in writing or by providing a copy of the publication document.

Recipient must not use or incorporate the reagent for commercial purposes.

Last Updated

February 20, 2015

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 02/20/2015 Page 2 of 2